Rockwell Medical Inc (RMTI) : Starfire Investment Advisers added new position in Rockwell Medical Inc during the most recent quarter end. The investment management firm now holds 13,200 shares of Rockwell Medical Inc which is valued at $79,860 , the company said in a statement filed on Oct 17, 2016 with the SEC.Rockwell Medical Inc makes up approximately 0.05% of Starfire Investment Advisers’s portfolio.
Other Hedge Funds, Including , Legal General Group Plc reduced its stake in RMTI by selling 1,324 shares or 12.96% in the most recent quarter. The Hedge Fund company now holds 8,894 shares of RMTI which is valued at $57,900. Cutler Group Lp sold out all of its stake in RMTI during the most recent quarter. The investment firm sold 11,700 shares of RMTI which is valued $79,911. Simplex Trading sold out all of its stake in RMTI during the most recent quarter. The investment firm sold 38,235 shares of RMTI which is valued $255,027.Bnp Paribas Arbitrage Sa boosted its stake in RMTI in the latest quarter, The investment management firm added 1,378 additional shares and now holds a total of 3,240 shares of Rockwell Medical Inc which is valued at $21,967.
Rockwell Medical Inc closed down -0.22 points or -3.51% at $6.05 with 2,84,999 shares getting traded on Friday. Post opening the session at $6.28, the shares hit an intraday low of $6.05 and an intraday high of $6.43 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Rockwell Medical Inc reported $-0.11 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.07. The company had revenue of $12.50 million for the quarter, compared to analysts expectations of $13.85 million. The company’s revenue was down -3.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.05 EPS.
Rockwell Medical Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency secondary hyperparathyroidism and hemodialysis. The Company’s lead branded drug Triferic is approved by the United States Food and Drug Administration (FDA). Triferic is an iron compound that is delivered to hemodialysis patients via dialysate replacing the iron loss that occurs during their dialysis treatment. Triferic enters the blood and immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Rockwell’s generic drug Calcitriol is indicated for treating secondary hyperparathyroidism in dialysis patients. The Company manufactures sells delivers and distributes hemodialysis concentrates along with a range of ancillary products.